Effects of Moringa oleifera leaves on CRP, MDA, and alevels in a mouse model of preeclampsia.

BACKGROUND: Preeclampsia is a serious pregnancy complication characterized by high blood pressure and organ dysfunction, primarily affecting the placenta and kidneys. Reduced placental blood flow can have severe consequences for both the mother and fetus, highlighting the need for effective treatment options. Moringa oleifera leaves, which are known for their potent antioxidant and anti-inflammatory properties, have been explored as a potential intervention to mitigate oxidative stress associated with preeclampsia. AIM: This study aimed to determine the effect of M. oleifera Leaves on C-reactive protein (CRP), Malondialdehyde (MDA), and albuminuria in a mouse model of preeclampsia. METHODS: This post controlled experimental study used a preeclampsia-induced mouse model. Female Mus musculus were assigned to five groups: (C0) negative control, (C+) positive control, (T1) treatment group 1 receiving 100 mg/kg BW/day of M. oleifera extract, (T2) treatment group 2 receiving 200 mg/kg BW/day, and (T3) treatment group 3 receiving 400 mg/kg BW/day. The extract was administered orally via gavage for 16 consecutive days, after which the mice were sacrificed. MDA, CRP, and albuminuria levels were measured using ELISA. RESULTS: Moringa oleifera supplementation significantly reduced MDA levels, with the lowest levels observed in the T3 group (22.44 ± 1.66). The T2 group exhibited the lowest CRP levels (2.64 ± 0.17), and albumiuria lowest level was observed in the T2 group (3.42 ± 1.09). CONCLUSION: Moringa oleifera administration effectively reduced MDA, CRP, and albuminuria levels. As an antioxidant and anti-inflammatory agent, M. oleifera helps suppress inflammation by lowering CRP levels, inhibiting lipid peroxidation to reduce MDA, and improving symptoms of preeclampsia, as evidenced by decreased albuminuria. These findings suggest that incorporating M. oleifera into dietary regimens may have therapeutic effects against preeclampsia-associated symptoms.